💡Dr. Alexa Meara illuminated opportunities for education and cross-collaboration between oncology and rheumatology in the immunotoxicity management context, emphasizing a precision medicine approach that not only targets the tumor, but also considers the patient as a whole.

📣Weekend Read: A recent study reveals that medication burden significantly increases acute care use in older metastatic prostate cancer patients on androgen receptor inhibitors. Read the full details on our website.🌐

Izalontamab shows promise as a safe treatment for advanced #epithelial tumors, demonstrating early antitumor activity in a recent #ClinicalTrial. #Oncology #Cancer

#ESMO25: A study reveals that lower KIM-1 levels predict better outcomes in advanced #RenalCellCarcinoma patients treated with nivolumab and ipilimumab. #biomarkers

New trial results reveal sacituzumab govitecan shows promise for HR+/HER2– metastatic #BreastCancer, despite missing primary survival goals.

📹 WATCH: Dr. Jonathan Strosberg @MoffittNews discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues and achalasia in patients. #NANETS2025

#ESMO25: New research identifies CD8+ PD-1+ TIM-3- LAG-3 TILs as promising #biomarkers for improved outcomes in metastatic clear cell #RenalCellCarcinoma treatments.

📹 WATCH: Dr. Michael Soulen discusses safety concerns and adverse events in #NeuroendocrineTumor treatments, highlighting cytopenia and radiation risks while ensuring patient safety. #NANETS2025

#ESMO25: The DISCUS trial reveals that shorter systemic therapy improves quality of life for advanced #UrothelialCancer patients, challenging traditional treatment durations.

#FDANews: The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk smoldering multiple myeloma.📣 🔗: https://t.co/zQ50jjwQiR

👨‍⚕️Afternoon Watch: Jason S. Starr, DO, discusses the significance of the extrapancreatic neuroendocrine tumor cohort of the phase 3 CABINET trial (NCT03375320) of cabozantinib. 💡 #CancerResearch #OncologyNews 🔗:

#ESMO25: Nivolumab plus visugromab showed superior efficacy to placebo and good tolerability in patients with newly diagnosed muscle-invasive bladder cancer, according to GDFATHER-NEO trial results.💡 🔗:

🌐 Results from the phase 1 RaDD trial radiotherapy added to immunotherapy enhanced responses, demonstrated manageable safety, and was informed by T-cell dysregulation in patients with B-cell lymphomas. ✔️ Read the full trial results here:

📣 FDA News: The FDA has granted orphan drug designation to the acute myeloid leukemia treatment candidate M2T-CD33 (LTI-214), signaling a potential entrance for a novel, differentiated therapeutic approach to this aggressive disease.💡 🔗: https://t.co/UcQO0ckjnj

☀️Morning Watch: Dr. Michael Soulen discusses the safety and efficacy regarding the novel combined treatment for neuroendocrine tumors that utilizes both systemic chemotherapy and peptide receptor radionuclide therapy at the 2025 NANETS Symposium.🌐 🔗:

💡 EDGE-Gastric trial: The combination of domvanalimab and zimberelimab showed a 59% objective response rate in advanced HER2-negative gastroesophageal cancer patients, with a median overall survival of 26.7 months. 🔗:

💡 TRIMM-2 Study: Talquetamab and daratumumab combination achieved an 82.4% overall response rate in relapsed/refractory multiple myeloma patients, with a median PFS of 21.2 months. Read the full trial results here:

#ESMO2025: A novel combination therapy shows promise for preserving kidneys in high-risk upper tract urothelial carcinoma, challenging traditional treatment methods. #Kidney #UrothelialCarcinoma

📹 WATCH: Experts explore a novel combined therapy for liver-dominant #neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT. #NANETS2025

📹 WATCH: Dr. Jonathan Strosberg discusses the promising results of the ALPHAMEDIX-02 trial, evaluating a new therapy for advanced neuroendocrine tumors. #NANETS2025